SCHEMBL20140303

SCHEMBL20140303

NC(=O)c1nc(Cc2ccccc2F)c2cccnn12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GUCY1A1 Q02108 6/20 0.44
GUCY1B1 Q02153 6/20 0.44
KCNH2 Q12809 3/20 0.44
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 4/20 0.38
PLK1 P53350 1/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDE4B Q07343 1/20 0.35
AR P10275 1/20 0.35
MAOB P27338 1/20 0.35
PARP15 Q460N3 1/20 0.35
PARP14 Q460N5 1/20 0.35
PARP10 Q53GL7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20140324 0.83 PDE4A (0.44) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL20140464 0.79 MAP2K3 (0.42) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL20140419 0.75 GUCY1A1 (0.37) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL14746623 0.72 PDE4B (0.39) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL14754744 0.71 GUCY1A1 (0.51) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
Acetic Acid SCHEMBL15647313 0.71 GUCY1A1 (0.53) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL21787186 0.70 AR (0.38) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL13738267 0.69 GUCY1A1 (0.47) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL19480652 0.68 GUCY1A1 (0.46) GUCY1A1GUCY1B1KCNH2MEN1KMT2A
SCHEMBL13739532 0.68 GUCY1A1 (0.48) GUCY1A1GUCY1B1KCNH2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3135/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3222/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3222/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A GUCY1A1 4/4885GUCY1B1 6/4885KCNH2 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.